TABLE 1.

Demographics and Functional Outcome: The Difference in Visual Acuity at Baseline vs Weeks 24 and 48

Pt	Dx	Age (years)	Gender	Previous Treatments	Duration (months)	BL	Wk 24	Wk 48	ΔWk 24	ΔWk 48
1	PM	57	F	None	26	3	27	30	24	27
2	BCR	50	F	PDT × 3 + Pegaptanib	16	33	47	39	14	6
3	PM	48	M	PDT × 4	15	7	20	19	13	12
4	OHS	51	M	Triamcinolone + PDT × 1	<1	14	55	50	41	36
5	AS	37	F	PDT × 6	14	26	60	53	34	27
6	PM	23	F	Pegaptanib	4	43	55	52	12	9
7	PM	48	F	None	1	25	42	47	17	22
8	OHS	58	M	Intravitreous Bevacizumab	4	38	49	47	11	9
9	PIC	41	M	PDT × 3	3	23	63	55	40	32
10	PIC	33	F	Triamcinolone	6	31	40	50	9	19
					Mean	24.30	45.80	44.20
					Median	25.50	48.00	48.50

PM = pathologic myopia; BCR = birdshot chorioretinopathy; OHS = ocular histoplasmosis syndrome; AS = angioid streaks; PDT = photodynamic therapy; PIC = punctate inner choroidopathy. Demographic information is shown for each patient (Pt) including: the diagnosis age, gender, previous treatments, and duration of choroidal neovascularization at baseline. The functional outcome is the number of ETDRS letters read at 4 meters at baseline (BL), week 24 (Wk 24), and Wk 48, and the difference in letters read between Wk 24 and baseline (ΔWk 24; the primary outcome measure) or Wk 48 and baseline (ΔWk 48).

Boldface indicates the change in visual acuity from baseline.